![](https://lemmy.world/pictrs/image/d8ebb99c-5366-4670-bc75-4ae53cd8c72e.png)
![](https://lemmy.world/pictrs/image/3d9e0457-3afb-4203-98e1-35253454ecbe.png)
Seems that trials are already happening. As a person living with UC, this could be a game changer.
Too late for me, but good news for those who come after.
Sounds too good to be true. Let’s hope it’s real.
God dammit, after I have my colon removed.
You and me both friend.
If this works out it would be a game changer, though most likely also priced as such especially if it is a one hit solution for diseases such as MS as there is a lot of money being made out of the current medication, hopefully it doesn’t get buried.
How does one keep up with developments on something like this?
It’s be a bit premature to do that, if you’re interested as a patient or layperson. It will also be all over the news in five years or so if it works and they bring it to market.
However, it looks like you could make an alert for the company name (Anokion SA) if you’re interested.
Those trials are conducted by the pharmaceutical company Anokion SA, which helped fund the new work and which Hubbell cofounded and is a consultant, board member, and equity holder
@baruchin The technology seems relatively simple and low-risk: tag a molecule with a specific sugar… I wonder if this is something biohackers can manage to do before clinical trials and Big Pharma approval. If so, sign me up! #biohacking
In mice